FC25: ​Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis: An Online Activity

In this 20-minute Seminar in Depth from the 2025 Fall Clinical Dermatology Conference, the faculty explore what differentiates TYK2 inhibitors from traditional JAK inhibitors, as well as how to identify patients with psoriasis who may benefit from oral small molecule therapy.

“When thinking about a medication, you need to take a number of things into consideration: location of disease, disease severity, and age. Age plays a big role when I think about what medication I’m going to choose for a patient – Are they of child-bearing age? Are they young and they live in group housing or a dorm?” – Benjamin Lockshin, MD

FC25: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis: An Online Activity

This activity is supported by an educational grant from Bristol Myers Squibb.